Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03859869 · ClinicalTrials.gov registry record · Phase 4
A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)
A Phase 4 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT03859869: Clinical Trial Phase 4 study, sponsored by AbbVie.
NCT03859869 is a Phase 4 study that was terminated before completion, run by AbbVie. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03859869, a Phase 4 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer. This study will include resected participants who are post pancreatic cancer surgery, and an additional cohort in non-resected participants.
Primary Outcome
Stool samples were collected during the 48 hours prior to the Day 1 and Week 1 visits and analyzed for fat content.
Interventions
- DRUG Placebo
- DRUG Pancrelipase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-02-25 |
| Est. Completion | 2022-03-23 |
| Phase | Phase 4 |
Why NCT03859869 stopped before completion
NCT03859869 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03859869 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03859869 about?
NCT03859869 is a clinical study titled "A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)". This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer. This study will include resected participants who are post pancreatic cancer surgery, and an additional cohort in non-resected participants.
What is the current status of trial NCT03859869?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2020-02-25. Estimated completion is 2022-03-23.
What interventions are being tested in trial NCT03859869?
The interventions under investigation include: Placebo (DRUG), Pancrelipase (DRUG).
Who is sponsoring clinical trial NCT03859869?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03859869's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI